Yahoo Finance

See 3 “Double Down” stocks »

*Stock Advisor returns as of November 11, 2024

GAAP, can also be found in the earnings materials that are available on our website. Lastly, we will be making statements regarding market share information throughout this conference call, and unless otherwise stated, all market share data is provided by Hifyre. We'll now make prepared remarks, and then we'll move to a question and answer session. With that, I'll pass it over to Cronos' chairman, president and CEO, Mike Gorenstein.

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

Thank you, Anna, and good morning, everyone. Our results this quarter prove that our long-term approach to this industry is paying off with record revenue this quarter and our disciplined approach to operating expenses were demonstrating our ability to simultaneously grow and increase efficiency across our business. Thanks to our strong balance sheet, we are exceptionally well positioned to capitalize on future growth opportunities and enhance our position in the current markets we operate in. Before getting into details on the quarter, I'd like to spend a minute on where we are from a flower supply demand perspective.

Over the past year, we have seen a rapid increase in demand for our flower products after taking market share in Canada and Israel. We've also seen additional growth in international markets, particularly Germany and the U.K. As a result, we have not been able to fully meet flower demand. We believe the driver of this increased demand is a combination of our genetic breeding program and the cultivation capabilities of GrowCo.

And with European growth picking up and the shortage of high quality flower in Canada, we only see demand increasing from here. That is why we announced the expansion of GrowCo. This investment involved an additional approximately $51 million credit facility to support the expansion of GrowCo's state of the art production facility. With this investment, Cronos obtained majority control of the board and began consolidating GrowCo into our results this quarter.

As I've mentioned before, GrowCo's strong performance has been significant, yet underappreciated. These consolidated results demonstrate a more complete picture of our whole business. Turning now to brand updates. In Q3, Spinach became the No.

1 ranked cannabis brand in the Canadian market with 4.8% market share supported by No. 1 rankings in edibles and flower, No. 4 in vapes, and No. 8 in pre-rolls.

The brand's market share outperformance represents our relentless commitment to quality, innovation, and bringing differentiated products to the competitive Canadian adult use market. In the edibles category, SOURZ by Spinach, our industry leading edibles, captured 17.2% of the market share in Q3 and today accounts for five of the top 10 best selling edibles in Canada. Our focus on developing innovative strategies and products in this category has been instrumental in our success. We recently launched our first seasonal offering, Caramel Green Apple SOURZ, which has been a huge hit with consumers.

In Q3, we also launched our Fully Blasted SOURZ in Ontario, a single ten milligram THC gummy. This has been the fastest selling launch in company history. This quarter, we also launched new SOURZ flavors with rare cannabinoids, our strawberry watermelon 4 to 1 gummy with CBG and THC and our Peach Passion Fruit gummy with CBN, CBD, and THC are now in market. Edibles from our Lord Jones brand are also doing well in the chocolate category, quickly growing to become the third best selling chocolate brand in Canada.

We look forward to seeing chocolate fusions perform during the holiday season and heading into the winter months, which tends to have a lift in the chocolate category. Spinach continues its exceptional performance in the flower category at the No. 1 spot in the Canadian market with 6% market share led by popular genetics such as GMO cookies, wedding cake, and space cake in a variety of sizes. This segment has also been bolstered by our milled flour offering, Spinach Grindz.

The continued success of our breeding program and GrowCo has further strengthened our position in this category, ensuring premium quality and consistency. The vape category continues to perform steadily. Spinach maintains the No. 4 position with 6.4% market share.

This quarter, we launched the new Spinach HITZ All-in-One vapes in pink lemonade and rocket icicle, as well as new flavors mango and grape for our one point two gram vapes. Our pink lemonade vape is now the No. 1 one point two gram vape. This is a competitive category, and we are committed to continuing to innovate and bring differentiated products, flavors, and cannabinoid combinations to market.

This quarter we saw an improvement in market share in the pre-roll category. In infused pre-rolls, Spinach saw 25% retail dollar sales growth, boosting our brand rank to sixth among all infused pre-roll brands. Lord Jones is shaping up to be a clear leader in hash infused pre-rolls in the Canadian market. The recently launched sour blueberry infused pre-roll ended Q3 as a top selling hash infused pre-roll.

The infused pre-roll category is growing, so we're particularly pleased to be winning here. We are laser focused on improving and innovating our pre-roll offerings, and we are seeing signs of that success roll through the numbers. But we still have plenty of room to grow in this space. We remain focused and optimistic about our plans for expansion.

Our strategy has always been to develop a portfolio of best selling and disruptive branded products we can launch in new markets as cannabis regulations open globally. The Spinach brand becoming the best selling brand in Canada is validation of our strong capabilities, and we're just getting started in expanding our winning portfolio of borderless products and bringing to markets globally. Now moving to Israel, our team there has shown remarkable performance throughout Q3 with record volumes sold and our best revenue quarter in two years. Cronos Israel built significant momentum throughout the year despite a very competitive market with declining patient growth, which is a testament to the strength and the quality of the Peace Naturals brand and products.

We are excited about the growth in Israel despite geopolitical factors affecting the region this past year, which gives us confidence in our position in this market. Internationally, we've made great strides in the markets we have entered. In Germany, our Peace Naturals brand continues to penetrate the market and grow at a strong clip. We are confident in the momentum we are seeing in the German market given we are selling the same products that led us to our number one flower position in Canada.

We believe we have a right to win and are well positioned to continue to take share in the German market. Similarly, while it's early days in the U.K., we are starting to grow our Peace Naturals brand and are excited about our growth potential. This quarter's success driven by our growing portfolio of borderless products, strong infrastructure and industry leading balance sheet enables us to not only expand in our existing markets but also to seize opportunities in any new market we choose to enter. Now I'll turn it over to James to walk you through the financials.

James Holm -- Chief Financial Officer

Thanks, Mike, and good morning, everyone. I will now review our third quarter 2024 results, which now include the consolidation of GrowCo's financials. The company reported consolidated net revenue of 34.3 million, a 38% increase from the prior year period. Net revenue from Cronos excluding GrowCo was 30 million, representing a 21% growth year over year on a stand-alone basis, while GrowCo net revenue was 4.3 million.

The net revenue increase was primarily driven by higher cannabis flower and extract sales in Canada, higher flower sales in Israel, and sales in other international countries which include Australia, Germany and the U.K. Gross profit in the third quarter was 3.6 million, equating to an 11% gross margin. Adjusting for the impact of the inventory step up from Cronos Growco transaction that was recorded in the cost of sales, our adjusted gross profit was 10.7 million equating to a 31% adjusted gross margin. We will continue providing this adjustment until the inventory that was stepped up to fair market value through the purchase accounting adjustment has been sold through as we believe it is useful in reviewing and evaluating our ongoing performance.

Year-over-year adjusted gross profit improved by 6.8 million and adjusted gross margin improved by 15 percentage points. The increase was primarily driven by higher sales in cannabis flower and extracts in Canada, higher cannabis flower sales in Israel, and sales in other international markets. Consolidated adjusted EBITDA in the third quarter was negative 6 million, representing a 9.2 million improvement from the prior year period. The improvement was driven by an increase in net revenue and a decrease in general and administrative expenses.

The disciplined approach to opex controls employed to date has put us well on our way to achieving our 2024 goal of saving an incremental 5 to 10 million for Cronos on a stand-alone basis, and we are tracking toward the high end of that range. However, the addition of GrowCo's opex into our consolidated financials are expected to offset these savings next year. Turning to the balance sheet and cash flow, the company ended the quarter with $862 million in cash and cash equivalents. Cash and cash equivalents were up 14 million from Q2, driven primarily by improved cash flow from operations and some FX fluctuations.

Cash flow from operations was positive 11.6 million compared to a negative 0.2 million in the prior year period and free cash flow was positive 5 million compared to a negative 0.5 million in the prior year period driven by an increase in adjusted gross profit and an income tax refund, a significant improvement. Looking back on the progress we have made, I share in Mike's confidence in the trajectory of our business and our preparedness for entry into new markets as they become available. With that, I would like to hand it back to Mike for a brief comment before going into Q&A.

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

In closing, we're proud of the record breaking progress we've made this quarter. Our strategies are delivering results, and we remain committed to building on this momentum as we close out the year. We'll continue to drive top line growth, improve margins and expand our international presence, positioning Cronos for long-term success. With that, I'll open the line for questions.

Questions & Answers:

Operator

Thank you. At this time, we will conduct the question and answer session. [Operator instructins] Our first question comes from Matt Bottomley of Canaccord Genuity. Your line is now open.

Matt Bottomley -- Canaccord Genuity -- Analyst

Yeah. Good morning, everyone. Thanks for the questions. Mike, I just wanted to start.

I know it's not really fundamental to the business, but I know you have a long standing -- some long-standing experience and knowledge in the U.S. sector. And I'm just curious, your thoughts, coming out of the election, you guys have obviously a very potent balance sheet potentially one day if there are opportunities down south. And just curious based on how these equities have reacted and flippant administration, any takeaways on your end of where you see the U.S.

going in the next year or so?

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

Thanks, Matt. That's a great question. I think there's still some uncertainty over the next next couple of weeks as we see the transition team come together and what that might mean. But, generally, I think as a matter of policy and incoming administration often pulled back and restarts all the pending regulatory rules.

Our understanding is that the Trump administration supports the States Act, and I think that's still something that's positive. But at a minimum, I would expect for the rescheduling efforts to restart the clock. So, if at all, schedule three I think is about 18 months away if there is going to be rescheduling. But we believe that building on the States Act and on some of the existing hemp frameworks are the way forward.

Big picture, what I'll say is that I think we're now actually in a very good position where we don't need to rely on that regulatory change given the growth we're seeing in Canada, Israel and the regulatory tailwinds in Europe and growth there.

Matt Bottomley -- Canaccord Genuity -- Analyst

OK. Interesting. Got it. And then just more on on the Cronos side of things.

So, yeah, just interesting some of the commentary you made on the dynamic you're seeing for your own branded flower and some of the genetics. I know you guys have a differentiation in that space of the market. But we have not heard in a very, very long time of LPs expanding capacity. So just the risk rewards of that and how it's specific to to the Cronos model relative to what we've seen over the last couple of years, which is some pretty ugly supply demand dynamics for maybe lower grade flower,

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

Yeah. Thanks. So I think we're in a fortunate position where early on a lot of our focus was more on genetic breeding on consumer insights and generally R&D on on cultivation methods, and we've seen flower demand steadily increase. So we've got SKUs that are at the top in Canada and Israel.

We're seeing really strong momentum in Europe, and I think we're in a position where we have to pick which markets we're filling. And that's just Cronos on its own. I think there's also a lot of demand from other LPs from GrowCo, but we feel like we would be performing much better in flower if we had more supply and that's really across markets. So I think as long as we continue to be focused on quality, the model of having GrowCo produce the genetics that we have in market, and the pipeline of genetics we have, which we're really excited about should continue to drive that success.

Matt Bottomley -- Canaccord Genuity -- Analyst

Awesome. Thanks. I'll leave it there.

Operator

Thank you. Our next question comes from Bill Kirk of Roth. Your line is now open.

Bill Kirk -- ROTH MKM -- Analyst

Hey. Thanks for taking the question. Mine is related to your last answer there, Mike. For for GrowCo, how should we think about the seasonality of the business, whether it's top line contribution or profitability contribution now that you're consolidating that? Like how should we think about the seasonality going forward? And then how is the resource allocation determined between your needs and third-party needs? How is that determined to make sure you get what you want but also sell into the customers that need it as well? Thank you.

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

Sure. Thanks. It's a great question. I think there's really not a lot of seasonality on the top line, especially given the shortage and where we are today.

You do have some slight slight deviations in terms of which seasons are the most efficient for production, how much power you need to pull for supplemental lighting versus heating and cooling. Sometimes you see the summer is not the best season to cultivate in. But just given the high tech nature of the greenhouse,that's still relatively smoothed over and pretty hard to notice a difference. And then overall, the way that we've structured the deal, we have a option, but not an obligation.

Until the second phase is online, we can purchase up to 80% of the supply at a preset price. And then once the second phase is online, that would expand current capacity today by 70%. We have a option, but not obligation to purchase up to 70% at a preset price. So we feel like it's a really good balance where we're able to make sure that we're only filling demand that we think is there and is right for the brand, but still significant upside to where we are today.

Bill Kirk -- ROTH MKM -- Analyst

OK. And then maybe I missed it in the prepared remarks, but there's like a step up in capex spending in the quarter relative to the levels that had been. What's behind that? Maybe I should already know this, but what's behind that? And does that signify any sort of change in kind of capital use intentions?

James Holm -- Chief Financial Officer

Hey, Matt. So the capex really was driven by that GrowCo phase two expansion, so we spent roughly $6.5 million in capex in Q3. We would expect increased capex levels along with that expansion until completion. So that's really the main driver there.

Bill Kirk -- ROTH MKM -- Analyst

And if we're thinking about it quarterly, around at the same level as 3Q? And what is the total capex expectation for that second phase?

James Holm -- Chief Financial Officer

Yeah. So Mike had highlighted that earlier, but at least we have granted them approximately $51 million. Right? It could be something a little bit south of that. But I would anticipate maybe semi evenly could be a little bit lumpy right over the next few quarters.

We do expect kind of that additional biomass to be online second half. So mid year is hopefully when the capex spend would complete for phase two if that helps.

Bill Kirk -- ROTH MKM -- Analyst

Thank you. It does.

Operator

[Operator signoff]

Duration: 0 minutes

Call participants:

Anna Shlimak -- Chief Strategy Officer

Michael Gorenstein -- Chairman, President, and Chief Executive Officer

James Holm -- Chief Financial Officer

Mike Gorenstein -- Chairman, President, and Chief Executive Officer

Matt Bottomley -- Canaccord Genuity -- Analyst

Bill Kirk -- ROTH MKM -- Analyst

More CRON analysis

All earnings call transcripts

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool recommends Cronos Group. The Motley Fool has a disclosure policy.

Cronos Group (CRON) Q3 2024 Earnings Call Transcript was originally published by The Motley Fool